TMS Co., Ltd Logo

TMS Co., Ltd

Develops small molecule drugs from natural compounds for the global pharmaceutical market.

4891 | T

Overview

Corporate Details

ISIN(s):
JP3544960002
LEI:
Country:
Japan
Address:
府中市府中町一丁目9番地京王府中1丁目ビル11階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TMS Co., Ltd. is a biotechnology company engaged in the research, development, manufacture, and sale of pharmaceuticals, quasi-drugs, drug substances, and medical devices. The company focuses on developing small molecule drug candidates derived from natural compound libraries, collaborating with academic institutions to bridge scientific discoveries with the global pharmaceutical market. Its research includes the development of SMTPs (Small Molecule Therapeutic Products), which have shown potential in promoting thrombolysis, suppressing inflammation, and providing antioxidation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 08:41
Report Publication Announcement
確認書
Japanese 7.9 KB
2025-10-15 08:40
Interim Report
半期報告書-第22期(2025/03/01-2025/12/31)
Japanese 212.5 KB
2025-05-30 03:20
Post-Annual General Meeting Information
臨時報告書
Japanese 27.5 KB
2025-05-30 03:18
Registration Form
確認書
Japanese 7.9 KB
2025-05-30 03:17
Governance Information
内部統制報告書-第21期(2024/03/01-2025/02/28)
Japanese 21.1 KB
2025-05-30 03:15
Annual Report
有価証券報告書-第21期(2024/03/01-2025/02/28)
Japanese 2.9 MB
2025-04-09 09:05
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-03-14 07:58
Registration Form
有価証券届出書(組込方式)
Japanese 407.4 KB
2025-02-28 07:37
Legal Proceedings Report
臨時報告書
Japanese 18.5 KB
2025-02-06 09:01
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2024-10-15 08:18
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-10-15 08:15
Interim Report
半期報告書-第21期(2024/03/01-2025/02/28)
Japanese 176.1 KB
2024-07-12 08:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-07-12 08:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/03/01-2024/05/31)
Japanese 125.8 KB
2024-05-29 03:27
Registration Form
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all TMS Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TMS Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TMS Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Pharmena S.A. Logo
Develops dietary supplements using its patented 1-MNA molecule to support healthy aging.
Poland
PHR
Bulgaria
PHRM
Pharmicell Co.,Ltd. Logo
Biopharma firm in stem cell therapies, biochemicals, cell banking, and stem cell cosmetics.
South Korea
005690
Pharming Group N.V. Logo
Develops & commercializes protein & precision medicines for rare, life-threatening diseases.
Netherlands
PHARM
Pharmocann Global Ltd. Logo
Develops pharma-grade medical cannabis products like oils, ointments, tablets, and cosmetics.
Israel
PMCN-M
Pharvaris N.V. Logo
Developing oral therapies for rare angioedema to treat and prevent attacks.
United States of America
PHVS
Phathom Pharmaceuticals, Inc. Logo
Develops and commercializes treatments for acid-related gastrointestinal diseases.
United States of America
PHAT
Pherecydes Pharma Logo
Develops precision phage therapy to treat resistant bacterial infections.
France
ALPHE
PHIBRO ANIMAL HEALTH CORP Logo
Develops animal health products, vaccines, and nutrition for livestock and companion animals.
United States of America
PAHC
Philogen Logo
Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.
Italy
PHIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.